Cardio-oncology Unit

In recent years, it has been observed that heart complications arising from cancer treatments (radiotherapy, chemotherapy, specific drug treatments) are one of the most significant causes of disease and, ultimately, mortality in surviving patients.

Advances in early detection and the development of new drugs and treatment plans have significantly improved patient survival (with survival rates of up to 90% in some cases over a 5-year period). However, despite this success in therapy, several studies have confirmed that there is an increased risk of cardiovascular complications in the long and medium term associated with the use of chemotherapy and radiotherapy.

Today, cardiovascular toxicity arising from cancer treatments is the most common cause of death in patients who have survived breast cancer. Therefore, the Teknon Oncology Institute has established a specific unit to minimise the cardiovascular effects of the best possible cancer treatment.

The Cardio-oncology Unit conducts an assessment of all patients diagnosed with cancer who are going to be treated with potentially cardiotoxic therapies. In addition, risk is identified based on the planned treatment and pre-existing cardiovascular risk factors are monitored.

The Cardio-oncology Unit (COU) at Centro Médico Teknon was created thanks to close multidisciplinary collaboration between the Teknon Oncology Institute and the Teknon Cardiology Institute, two renowned institutes in their respective fields. The unit enables the best possible cancer treatment to be administered while minimising cardiovascular effects, ensuring comprehensive and continuous care for cancer patients.

For further information, please contact the Teknon Oncology Institute:

Phone. 93 290 64 71